Project description
Breaking barriers to treat paediatric brain tumours
Paediatric brain tumours, particularly diffuse intrinsic pontine glioma (DIPG) and glioblastoma, stand as formidable adversaries with no current cure and dismal prognoses. The blood-brain barrier adds an extra layer of complexity, hindering effective therapeutic interventions in the brain. In response, the EU-funded G2B-002 project is supporting Spain-based Gate2Brain in spearheading a transformative initiative; it will leverage a pioneering peptide-based technology to breach biological barriers and revolutionise treatments for these devastating paediatric diseases and other central nervous system diseases in the future. The project aims to catalyse breakthroughs, offering newfound hope in the fight against these rare yet lethal afflictions.
Objective
Gate2Brain (G2B) is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier (BBB). Using this radically innovative peptide-based patented technology platform, G2B has developed a novel therapy, G2B-002, for pediatric brain tumors such as Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma, currently without a cure or poor prognosis.
Small and medium-size enterprises (SMEs) represent 99% of all business in the EU. G2B will apply to obtain SME designation to have access to finance and EU support programs which include research, competitiveness, and innovation funding. Another potential benefit that G2B could obtain is the fewer requirements or reduced fees for EU administrative compliance. G2B is mainly focused on pediatric brain cancer, a rare but mostly lethal Central Nervous System disease. After obtaining SME designation, G2B will develop the Paediatric Investigational Plan (PIP) included in the EU Paediatric Regulation. Thus, G2B expects also to benefit from: (i) reduction of registration taxes; (ii) tax deductions; (iii) access to financial support; (iv) assistance in the drafting of clinical trial protocols; (v) ease of access to procedures to accelerate marketing in Europe; (vi) right to marketing exclusivity for 10 years in Europe; and (vii) 6-month extension patent protection initiative of medicines for children.
The Health Economics & Market Access Outcomes Strategy that G2B will also perform will include a willingness-to-pay and product-market fit analysis, between others. The final report will help to estimate the economic value of the company considering relevant alternatives for both the healthcare system and pharmaceutical industry.
The R&D strategy of G2B is focused on the therapeutic validation of its Platform to demonstrate its safety and efficacy. With SME designation and PIP, G2B will be able to successfully initiate first in human clinical trials in pediatric population.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences sociology governance taxation
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.2 - European innovation ecosystems
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-CSA - HORIZON Coordination and Support Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIE-2022-SCALEUP-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08028 Barcelona
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.